BGLC vs LLY · rev $99.0K vs P/E 39, rev $22.97B
BioNexus Gene Lab Corp Common stock (BGLC) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Latest reported BGLC revenue for 2026-06-30 was $99.0K. Net income was -$830.0K. BGLC currently screens at market cap $6.1M.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
BGLC currently screens at market cap $6.1M. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the BGLC and LLY stock pages for the full models.
Not investment advice.